

Catalog# BP-50540

## Ustekinumab Biosimilar, Human IL-12 / IL-23 Monoclonal Antibody

Ustekinumab is a human anti-IL-12 / IL-23 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralizes interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Ustekinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn's Disease and other autoimmune and inflammatory disorders. Ustekinumab biosimilar uses the same protein sequences as the therapeutic antibody Ustekinumab.

| Product Details       |   |
|-----------------------|---|
| CAS No.               | 815610-63-0   |
| Species Reactivity    | Human   |
| Source                | Mammalian cells   |
| Isotype               | Human IgG1 lambda                                       |
| Class                 | Monoclonal  |
| Type                  | Antibody  |
| Clone                 | Ustekinumab Biosimilar                                  |
| Conjugate             | Unconjugated  |
| Immunogen             | Human interleukin-12 (IL-12) and interleukin-23 (IL-23) |
| Purity                | >95%  |
| Molecular Weight      | 145.63 kDa  |
| Protein Concentration | 1 mg/ml   |
| Formulation           | 0.2 µM filtered PBS solution, pH 7.4                    |
| Storage conditions    | 4°C for short time, -20°C or -80°C for long time.       |